Levodopa-carbidopa intestinal gel may prove more effective for long-term treatment of PD
Report in the Journal of Parkinson's Disease presents data from one-year trial on long-term safety, efficacy, and quality of life in advanced PD patients using levodopa-carbidopa intestinal... (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - March 3, 2015 Category: Neurology Tags: Parkinson's Disease Source Type: news
Levodopa-Carbidopa intestinal gel may prove more effective for long-term treatment of Parkinson's disease than standard Levodopa
Data from one-year trial on long-term safety, efficacy, and quality of life in advanced Parkinson's disease patients using levodopa-carbidopa intestinal gel has been released by researchers, suggesting that it may be an effective long term treatment for the illness. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 26, 2015 Category: Science Source Type: news
Levodopa-carbidopa intestinal gel may prove more effective for long-term treatment of PD
(IOS Press) Continuous dosing via a levodopa-carbidopa intestinal gel (LCIG, now carbidopa and levodopa enteral suspension in the US) directly into the small intestine may be the key to reducing the motor complications associated with long-term levodopa use. In the current issue of the Journal of Parkinson's Disease, researchers report on the safety and efficacy of LCIG therapy over a one-year period. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 26, 2015 Category: Global & Universal Source Type: news
New therapeutic principle for Parkinsonian dyskinesia shows clinical effect
Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson's disease. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - February 11, 2015 Category: Neurology Tags: Parkinson's Disease Source Type: news
New therapeutic principle for Parkinsonian dyskinesia shows clinical effect
Involuntary dyskinetic movements induced by treatment with levodopa are a common problem for people with Parkinson's disease. Now, however, researchers seem to be close to a novel therapy to this distressing side effect. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 11, 2015 Category: Science Source Type: news
Duopa (Carbidopa and Levodopa Enteral Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 26, 2015 Category: Drugs & Pharmacology Source Type: news
Rytary (Carbidopa and Levodopa Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 16, 2015 Category: Drugs & Pharmacology Source Type: news
FDA Clears Enteral Suspension (Duopa) for Parkinson's FDA Clears Enteral Suspension (Duopa) for Parkinson's
Duopa (AbbVie) enteral suspension is given via a portable infusion pump that delivers carbidopa and levodopa into the small intestine for 16 hours to reduce motor fluctuations. FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 12, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
AbbVie Says Duopa Approved for Advanced Parkinson's Disease
Duopa (carbidopa and levodopa) enteral suspension treats motor fluctuations for people with advanced Parkinson's (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 12, 2015 Category: Pharmaceuticals Source Type: news
FDA Okays Carbidopa/Levodopa ER (Rytary) in Parkinson'sFDA Okays Carbidopa/Levodopa ER (Rytary) in Parkinson's
Approval of the extended-release carbidopa-levodopa formulation was based on positive results in a trio of phase 3 studies of patients with early and advanced PD. FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 8, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Adjunct Zonisamide Beneficial in Dementia With Lewy Bodies
Zonisamide as an adjunct to levodopa improves parkinsonism without worsening cognitive function (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - November 11, 2014 Category: Psychiatry Tags: Neurology, Pharmacy, Psychiatry, Journal, Source Type: news
Do dopamine drugs lead to compulsive shopping?
Conclusion
This study analysed serious adverse drug events reported to the US FDA over a 10-year period, and found that 710 events (just under half of all impulse control disorders reported during this period) were attributed to dopamine receptor agonists. Most of these disorders involved gambling, followed by hypersexuality and compulsive shopping.
This group of six drugs are used in Parkinson’s disease (and a small number of other conditions) where there is a lack of the chemical dopamine. The drugs act directly on dopamine receptors, effectively taking the place of dopamine and stimulating the receptor in the same wa...
Source: NHS News Feed - October 23, 2014 Category: Consumer Health News Tags: Mental health Neurology Medication Source Type: news
Changes in 'Parkinson's walk' predict dementia
Conclusion
Parkinson's is a neurological disease with characteristic features of tremor, rigidity and slow movements, as well as a variety of other classic symptoms, including Parkinson's dementia.
This case-control study demonstrates how measures of both gait (walking) and cognition are, as would be expected, poorer in people newly diagnosed with Parkinson's disease compared with healthy controls.
The study also demonstrates that in Parkinson's disease, people with a predominant postural instability and gait disorder (PIGD) unsurprisingly have poorer measures of gait than people with predominant tremor disorder (TD).
T...
Source: NHS News Feed - October 22, 2014 Category: Consumer Health News Tags: Neurology Older people Source Type: news
Depression 'common' in early Parkinson's
Conclusion
This cohort study benefits from its prospective design, following a group of people newly diagnosed with Parkinson’s disease across the course of two years compared to a group of healthy controls. It also benefits from being an international, multicentre study including a fairly large sample size, and from conducting regular symptom assessments using a series of validated tools.
However, there was quite a high loss to follow-up. From 423 people with Parkinson’s assessed at study start, 62% were available for 12 month follow-up, and only 23% at 24 months. This is an important limitation that may affect the re...
Source: NHS News Feed - August 18, 2014 Category: Consumer Health News Tags: Mental health Neurology Source Type: news
Depression 'common' in early Parkinson’s
Conclusion
This cohort study benefits from its prospective design, following a group of people newly diagnosed with Parkinson’s disease across the course of two years compared to a group of healthy controls. It also benefits from being an international, multicentre study including a fairly large sample size, and from conducting regular symptom assessments using a series of validated tools.
However, there was quite a high loss to follow-up. From 423 people with Parkinson’s assessed at study start, 62% were available for 12 month follow-up, and only 23% at 24 months. This is an important limitation that may affect the re...
Source: NHS News Feed - August 18, 2014 Category: Consumer Health News Tags: Mental health Neurology Source Type: news
